J
J. Rischen-Vos
Researcher at Erasmus University Rotterdam
Publications - 17
Citations - 587
J. Rischen-Vos is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 10, co-authored 17 publications receiving 578 citations.
Papers
More filters
Journal ArticleDOI
Proteinuria after renal transplantation affects not only graft survival but also patient survival.
Joke I. Roodnat,Paul G.H. Mulder,J. Rischen-Vos,I. C. van Riemsdijk,T. van Gelder,Robert Zietse,J. N. M. Ijzermans,W. Weimar +7 more
TL;DR: The presence of glomerulonephritis, hypertension, and systemic diseases as the original disease significantly increased the risk of graft failure with an increasing amount of proteinuria at 1 year, and both the risks for cardiovascular and for noncardiovascular death were increased.
Journal ArticleDOI
The vanishing importance of age in renal transplantation.
Joke I. Roodnat,Robert Zietse,Paul G.H. Mulder,J. Rischen-Vos,T. van Gelder,J. N. M. Ijzermans,W. Weimar +6 more
TL;DR: Considering the improving results over time, there are, at this moment, no arguments for an age restriction for kidney transplant recipients or donors.
Journal ArticleDOI
Cholesterol as an independent predictor of outcome after renal transplantation
Joke I. Roodnat,Paul G.H. Mulder,Robert Zietse,J. Rischen-Vos,I. C. van Riemsdijk,J. N. M. Ijzermans,W. Weimar +6 more
TL;DR: It is shown that whereas the RR for over-all graft failure in young recipients of a renal transplant increases significantly with higher cholesterol levels, there is very little influence on the RR of elderly recipients.
Journal ArticleDOI
Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients
Marinus A. van den Dorpel,Hosam Ghanem,J. Rischen-Vos,Arie J. Man in 't Veld,Hans Jansen,Willem Weimar +5 more
TL;DR: Treatment with CsA increases the susceptibility of LDL to in vitro oxidation, and also enhances the oxidation of LDL in vivo, which results in a more favorable lipid profile, which in combination with a lower arterial pressure and better renal function may decrease the risk for atherosclerosis.
Journal ArticleDOI
Losartan, an angiotensin-II receptor antagonist, reduces hematocrits in kidney transplant recipients with posttransplant erythrocytosis
Robert J.l. Klaassen,Teun van Gelder,J. Rischen-Vos,Jaap Deinum,Arie J. Man't Veld,Willem Weimar +5 more
TL;DR: Blockade of the type 1 angiotensin II receptor is safe and effective in treating posttransplant erythrocytosis and is concluded to be safe andeffective.